Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | TSHR | P16473 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | BLM | P54132 | 3/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | MPO | P05164 | 2/20 | 0.66 |
| ▸ | PTPRA | P18433 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 4/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248870 | 1.00 | KMT2A (0.66) | KMT2ATSHRKDM4ELMNAMAPT | |
| SCHEMBL18029199 | 1.00 | KMT2A (0.66) | KMT2ATSHRKDM4ELMNAMAPT | |
| SCHEMBL2330930 | 1.00 | KMT2A (0.66) | KMT2ATSHRKDM4ELMNAMAPT | |
| SCHEMBL30381733 | 1.00 | KMT2A (0.66) | KMT2ATSHRKDM4ELMNAMAPT | |
| SCHEMBL120340 | 1.00 | KMT2A (0.66) | KMT2ATSHRKDM4ELMNAMAPT | |
| SCHEMBL4262937 | 0.89 | HTR2A (0.60) | KMT2ATSHRKDM4ELMNAMAPT | |
| SCHEMBL4262934 | 0.89 | HTR2A (0.60) | KMT2ATSHRKDM4ELMNAMAPT | |
| Fluorotryptophane SCHEMBL125000 | 0.89 | HTR2A (0.73) | KMT2ATSHRKDM4ELMNAMAPT | |
| Fluorotryptophane SCHEMBL29623154 | 0.89 | HTR2A (0.73) | KMT2ATSHRKDM4ELMNAMAPT | |
| Fluorotryptophane SCHEMBL29358068 | 0.89 | HTR2A (0.73) | KMT2ATSHRKDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250042961-A1 | P53 PEPTIDOMIMETIC MACROCYCLES | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) | 2025-02-06 | — | — | US | claimed |
| US-20240350681-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-10-24 | — | — | US | claimed |
| CN-118829648-A | P53 peptidomimetic macrocycles | 默沙东有限责任公司 | 2024-10-22 | — | — | CN | claimed |
| EP-4444740-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | Merck Sharp & Dohme LLC (US) | 2024-10-16 | — | — | EP | claimed |
| US-11992537-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-05-28 | — | — | US | claimed |
| WO-2023107353-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | MERCK SHARP & DOHME LLC (US) | 2023-06-15 | — | — | WO | claimed |
| CN-108315370-A | A kind of preparation method of halogen tryptophan | 滨海吉尔多肽有限公司 | 2018-07-24 | — | — | CN | claimed |
| EP-0021585-B1 | TRUNCATED SOMATOSTATIN ANALOGS AND INTERMEDIATES THEREFOR, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE ANALOGS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1983-01-19 | — | — | EP | claimed |
| EP-0021585-A1 | Truncated somatostatin analogs and intermediates therefor, processes for their preparation, and pharmaceutical compositions containing the analogs | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-01-07 | — | — | EP | claimed |
| US-4225472-A | Truncated somatostatin analogs | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-09-30 | — | — | US | claimed |
| CN-122074077-A | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte stimulating hormone analogs for imaging or therapy | 省卫生服务机构 | 2026-05-22 | — | — | CN | disclosed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-0021585-A1 | Truncated somatostatin analogs and intermediates therefor, processes for their preparation, and pharmaceutical compositions containing the analogs | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-01-07 | — | — | EP | disclosed |
| EP-0021585-A1 | Truncated somatostatin analogs and intermediates therefor, processes for their preparation, and pharmaceutical compositions containing the analogs | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4225472-A | Truncated somatostatin analogs | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-09-30 | — | — | US | disclosed |
| US-4225472-A | Truncated somatostatin analogs | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11992537-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | MC1R, MC5R, MC3R | KMT2A 1625/4885TSHR 65/4885KDM4E 4278/4885 |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | SSTR2, SSTR4, SSTR5 | KMT2A 1730/4885TSHR 16/4885KDM4E 3869/4885 |
| US-20240350681-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | MC1R, MC3R, MC5R | KMT2A 1737/4885TSHR 81/4885KDM4E 4233/4885 |
| US-20250042961-A1 | P53 PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | KMT2A 4593/4885TSHR 2072/4885KDM4E 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.